Low doses of drugs delivered at close, regular intervals are increasingly being used to manage patients with different neoplasms. Despite the good tolerability, treatment-related adverse events still occur following metronomic protocols. The aim of this study was to retrospectively investigate whether polymorphisms of different genes involved in fluoropyrimidine metabolism and 5-fluorouracil (5-FU) degradation rate were associated with the outcome of a lowdose capecitabine schedule. Genotyping of DPYD IVS14 + 1 G > A, MTHFR C677T, and A1298C single-nucleotide polymorphisms was performed by pyrosequencing technology. A PCR technique was used for genotyping TYMS-TSER. Using peripheral blood mononuclear cells, we also evaluated the 5-FU degradation rate, which determines the net result of all the enzymatic transformation of 5-FU, in terms of the amount of drug consumed by the cells in a time unit. The association of these variables with clinical outcome was evaluated using multivariate logistic regression analysis. Eighty-four patients with metastatic gastrointestinal cancer, who had been treated with a lowdose fluoropyrimidine schedule, as a rescue therapy were included in the study. The TSER 2R/2R genotype was significantly associated with both hematologic (odds ratio = 7.90, P = 0.002) and gastrointestinal toxicity (odds ratio = 3.24, P = 0.009). Because DPYD IVS14 G > A singlenucleotide polymorphism was not observed in the cohort, it was excluded from the statistical analysis. No significant association was detected between clinical outcome and both MTHFR polymorphisms and the 5-FU degradation rate. In the advanced setting of cancer care, high attention should be paid toward avoiding toxicity and worsening of quality of life. Although metronomic chemotherapy is generally well tolerated, treatment toxicity nonetheless does occur. Our data suggest a possible role of the TSER 2R/2R polymorphism as a predictive marker of toxicity in patients treated with low-dose capecitabine. Anti-Cancer Drugs
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Introduction
Essentially, metronomic chemotherapy consists of longterm administration of low doses of cytotoxic drugs, administered at short intervals between consecutive doses, aimed at reducing proliferating tumor endothelial cells [1] [2] [3] . This antiangiogenic effect would counteract the tumor growth as well as the development of drug resistance [4] . Metronomic chemotherapy has been widely used in clinical studies including those of heavily pretreated or frail patients with cancers of different origin [5] such as that of the gastrointestinal tract [6] [7] [8] [9] . We showed in previous studies that, although metronomic schedules are characterized by a good toxicity profile, hematologic or gastrointestinal adverse events do occur in about 20% of the cases [7, 8] . Thus, considering the patients' settings, where quality of life becomes a primary end point of therapy, toxicity should be monitored closely to avoid the occurrence of severe adverse events.
Several common single-nucleotide polymorphisms (SNPs) such as methylentetrahydrofolate reductase (MTHFR) 677 C > T and 1298 A> C [10] , dihydropyrimidine dehydrogenase (DPYD) IVS14 G> A [11] , and thymidylate synthase enhancer region (TSER) in the promoter of the thymidylate synthase (TYMS) gene [12] have been related to the clinical outcomes of 5-fluorouracil (5-FU)-based chemotherapy.
MTHFR is a key enzyme regulating intracellular folate levels, which affect DNA synthesis and methylation. It is conceivable that tumors with deficient MTHFR variants such as 677T may be more sensitive to 5-FU cytotoxicity than tumors bearing the common MTHFR variant 677C. Moreover, this gene polymorphism has also been considered a potential factor for 5-FU toxicity [10] .
Dihydropyrimidin dehydrogenase promotes the degradation of 5-FU, which results in the formation of dihydrofluorouracil that transforms into fluoro-β-alanine before urinary elimination. Several genotypes have been associated with reduced enzyme activity and severe toxic side effects of 5-FU [11] , the most important being a point mutation in the splice site of intron 14 (IVS14 + 1 G > A) resulting in the deletion of exon 14 and thus in a nonfunctional enzyme [13] .
Thymidylate synthase (TS), the rate-limiting enzyme in de novo pyrimidine biosynthesis, is the target enzyme of fluoropyrimidines. The TSER (two to nine 28-bp repeats) polymorphism is recognized to be an independent predictor of tumor response in metastatic colorectal cancer (CRC) patients treated with 5-FU-based chemotherapy [12] . Moreover, it has been shown to correlate with progressionfree survival in CRC patients treated with capecitabinebased chemotherapy [14, 15] . Furthermore, an association between the TSER 2R/2R genotype and toxicity has been shown in both gastric cancer patients receiving cisplatin and 5-FU [16] and in patients with CRC treated with fluoropyrimidine-based chemotherapy [17] [18] [19] [20] [21] .
Finally, the assessment of the 5-FU degradation rate in the peripheral blood mononuclear cells (PBMC) of patients, before 5-FU administration, has been suggested as a prescreening method for evaluating the possible toxicity of the drug [22, 23] .
Data on both polymorphisms of the above-mentioned genes and 5-FU degradation rate in relation to the outcomes of metronomic fluoropyrimidines are still missing. Hence, we carried out a study aimed at retrospectively evaluating the impact of each of the following gene polymorphisms: MTHFR C667T, MTHFR A1298C, DPYD IVS14 G > A, TSER, and the 5-FU degradation rate on outcomes of metronomic capecitabine (mCAP) in patients with metastatic gastrointestinal cancer.
Patients and methods

Patients
This was a retrospective study carried out by a single institution. Clinical data were collected from records of consecutive patients with advanced gastrointestinal tumors treated with low-dose capecitabine (1500 mg every day orally) over a 5-year period. Patients had received this fluoropyrimidine regimen on the basis of the following parameters: histological diagnosis of upper (stomach, pancreas) or lower (colon, rectum) gastrointestinal tract cancer; progressive disease at baseline; inability to receive standard chemotherapy because of toxicity concerns or failure of one or more previous chemotherapeutic lines of treatment for metastatic disease; age of at least 18 years; performance status (Eastern Cooperative Oncology Group) of up to 3; life expectancy of more than 3 months as judged clinically; adequate bone marrow, renal and liver function (leukocyte count ≥ 3000/mm 3 ; platelet count ≥ 100 000 mm 3 ; creatinine < 2.0 mg/dl; total bilirubin levels ≤ 1.5 mg/dl; and transaminase values < three times normal values). Exclusion criteria for the treatment were as follows: brain metastases, symptomatic cardiac disease; recent history of myocardial infarction; active infections, inflammatory bowel disease; and pregnancy.
Our clinical practice considers monthly assessment of treatment toxicity according to the National Cancer Institute-Common Terminology Criteria for Adverse Events, version 3 (CTCAE v. 3, 2006) . Results of blood test along with other routine analysis are usually reported at the follow-up visit. During the follow-up visit, common toxicity is investigated and a great attention there is in recalling gastrointestinal toxicity in patients receiving chemotherapy for gastrointestinal cancer. Total toxicity was defined as the percentage of patients who had at least one adverse event irrespective of type. Clinical benefit (CB), which reflected the proportion of patients with complete responses, partial responses, and stable disease, was assessed according to the RECIST criteria and used to evaluate the activity of metronomic chemotherapy.
This study was carried out in accordance with the Declaration of Helsinki and the protocol approved by the institutional (Sapienza University, Rome, Italy) ethical committee (Rif. 3762_2015/23.07.2015, Prot. 2377/2015).
MTHFR, DPYD, and TYMS-TSER polymorphism genotyping
Genomic DNA was isolated from blood samples using the X-tractor gene system (Corbett Life Science, Sydney, Australia). The DNA polymorphisms MTHFR C677T (rs1801133), MTHFR A1298C (rs1801131), DPYD IVS14 + 1 G > A (rs3918290), and TSER 28-bp tandem repeat (rs34743033) were analyzed. Reference sequences for DPYD and TYMS genes were obtained from the NCBI GenBank database (http://www.ncbi.nlm.nih.gov/). Genotyping of DPYD IVS14 IVS14 + 1 G > A, MTHFR C677T, and A1298C SNPs was performed by pyrosequencing technology using the Pyrosequencer PyroMark ID system (Qiagen, Hilden, Germany). Both the amplification (5′-CATATTGGTGT CAAAGTG-3′; 5′-Biotin-TGGCAGATTCTTTAATAA-3′) and the sequencing (5′-AAAGGCTGACTTTCCAGA-3′) primers for the DPYD IVS14 polymorphism were obtained using the PSQ Assay Design software (Biotage AB and Biosystems, Uppsala, Sweden). MTHFR SNPs were analyzed by pyrosequencing technology using the commercial kit for 'fluoro-pyrimidine response' (Diatech, Iesi, Italy) according to the manufacturer's protocol. Briefly, the region covering the SNPs of interest was amplified as follows: after initial denaturation (95°C, 3 min), a thermal cycler protocol (35 cycles) was used cycling 30 s at 95°C, 30 s at 60°C, followed by 30 s extension at 72°C; a final extension of 5 min at 72°C was included. The PCR reaction was performed in a final volume of 25 µl containing 40 ng of genomic DNA, 10 pmol of each primer, 0.2 mmol/l dNTPs, 1.5 mmol/l MgCl 2 , PCR buffer, and 1 U of Taq DNA polymerase (Takara Bio Inc., Otsu, Japan). Single-stranded DNA was isolated from the PCR reaction using the Pyrosequencing Vacuum Prep Workstation (Biotage, Uppsala, Sweden) and Streptavidin Sepharose High Performance beads (Amersham Biosciences, Uppsala, Sweden) that bind to the biotinylated primer. After washing in 70% ethanol, incubation in denaturing buffer, and flushing with wash buffer, the beads were then released into a 96-well plate containing annealing buffer and the specific sequencing primer. Annealing was performed at 80°C for 2 min, followed by cooling at room temperature. Then, real-time sequencing was performed.
The polymorphism in TYMS-TSER, consisting of tandem repeats of 28 bp, was genotyped by classical PCR and visualized by electrophoresis on a chip (Agilent 2100 Bioanalyzer; Applied Biosystems, Foster City, California, USA). The PCR primer sequences were as follows: 5′-GTGGCTCCTGCGTTTCCCCC-3′; 5′-GCTCCGA GCCGGCCACAGGCATGGCGCGG-3′.
A PCR reaction was set up in a final volume of 25 µl containing 40 ng of genomic DNA, 10 pmol of each primer, 0.2 mmol/l dNTPs, 1.5 mmol/l MgCl 2 , PCR buffer, DMSO 4%, and 1 U of Taq DNA polymerase (Takara Bio Inc.). PCR amplification was performed at the following temperatures: 95°C for 1 min; 35 cycles of 95°C for 20 s, 60°C for 10 s, 72°C for 10 s; and 72°C for 5 min. The most common alleles are the double repeat (2R) and the triple repeat (3R), corresponding to fragments of 214 and 242 bp, respectively. Hardy-Weinberg equilibrium was assessed [24] .
Determination of the 5-fluorouracil degradation rate
The individual 5-FU degradation rate was assessed as reported previously [22] . Briefly, PBMC were isolated by Ficoll gradient centrifugation from blood samples collected between 9 and 10 a.m. to avoid changes in dihydropyrimidin dehydrogenase activity because of its circadian rhythm and counted using a Sysmex XE 2100 cell counter (Sysmex Canada, Missisauga, Ontario, Canada). A reaction mix containing 2-4 × 10 6 cells in PBS containing a fixed concentration of 5-FU was then incubated in a thermomixer at 37°C for 2 h. The degradation rate was determined by measuring the decrease in 5-FU added to the solution of intact PBMC. The analysis was carried out using the aforementioned liquid chromatogarphy-mass spectrometry/mass spectrometry method [22] . The degradation rate was calculated as ng/ml of degraded 5-FU 10 6 cells/min. Patients were categorized into two groups according to their value of the 5-FU degradation rate as reported previously [23] : below the 5th centile [poor metabolism (PM)] or above the 95th centile [ultrarapid metabolism (UM)] and within the 5-95th centile (0.85-2.2 ng/ml/10 6 cells/min).
Statistical analysis
SPSS statistical software, version 22 (SPSS Inc., Chicago, Illinois, USA), was used. χ 2 -Test or Fisher's exact test was used when appropriate for testing the association of MTHFR and TYMS-TSER genotypes and the 5-FU degradation rate with all other characteristics. The investigated genotypes were coded as follow: MTHFR C677T (CC, CT, TT), MTHFR A1298C (AA, AC, CC) and TSER (3R/3R, 3R/2R, 2R/2R). Logistic regression analysis was carried out to model the association between clinical-pathological parameters and the MTHFR or the TSER genotype adjusting for age sex and Eastern Cooperative Oncology Group performance status. Interaction effects were also tested for MTHFR and TSER genotypes. A P value of 0.05 was considered statistically significant.
Results
Eighty-four patients with advanced gastrointestinal cancer treated with low-dose capecitabine at our institution were included in the study. The baseline and demographic characteristics for these patients are shown in Table 1 . Most patients had a PS of 1. The median age was 69 (range: 30-85) years. The majority of patients had multiple sites of metastatic disease, with the most common disease spread to the liver (61.2%), lungs, and nodes (56.5%). Almost all patients were heavily pretreated with a median of two previous chemotherapy regimens (range: 0-4). The median duration of metronomic chemotherapy was 3 (range: 0.5-28) months. Among 78 patients who had completed at least one cycle of therapy, 27 (34.6%) developed one or more grades 1 − 2 adverse events ( Table 2 ). Neither grades 3-4 toxicity nor toxic deaths were recorded. At the time of the analysis, 63 patients had died; the median progression-free survival and OS were 3 and 6 months, respectively. There were three (4%) objective responses and 18 (23%) stable diseases, with overall 27% CB.
Pharmacogenetic variants analyses
Because DPYD IVS14 G > A SNP was not observed in the cohort, it was excluded from the statistical analysis. The distribution of these genotypes did not deviate from Hardy-Weinberg equilibrium (MTHFR 677, P = 0.68; MTHFR 1298, P = 0.58; TYMS-TSER, P = 0.84). Table 3 , the TSER genotype was significantly associated with toxicity and on carrying out a multivariate regression analysis, it was found to be an independent predictive factor. Indeed, patients harboring the TSER 2R/2R genotype were at the highest risk of developing hematologic, gastrointestinal, and total toxicity. It remained an independent predictive factor of toxicity in a multivariate regression analysis that also included MTHFR 677 and MTHFR 1298. The interaction terms between TSER and either MTHFR 677 or MTHFR 1298 were not found to be significant (P = 0.55 and 0.10 respectively).
As shown in
No association was detected between MTHFR and TSER genotypes and the achievement of clinical benefit from chemotherapy (data not shown).
Degradation rate of 5-fluorouracil
Overall, the mean value SD of 5-FU degradation rate was 1.57 0.40 (range: 0.70-2.57) ng/ml/10 6 cells/min. Four patients had a 5-FU degradation rate of less than 0.86 ng/ml/10 6 cells/min (PM) and four had more than 2.1 ng/ml/10 6 cells/min (UM). Four out of eight (50%) PM/UM patients showed grades 1-2 toxicities (one anemia, two diarrhea and one HFS) compared with 36% of normal-metabolizer patients (P = 0.65). No association between the 5-FU degradation rate and each evaluated genotype or clinical outcome (toxicity and CB) was detected ( Table 4 ).
Discussion
There is evidence of clinical benefits following long-term metronomic chemotherapy with capecitabine in chemotherapy-resistant cancer patients [5] [6] [7] [8] [9] . To some extent, this depends on a multitarget action on cancer of such a treatment, rather than an exclusive antiangiogenic function as reported earlier [5] . Although continuous low-dose capecitabine is generally well tolerated, treatment toxicity has been reported [6] [7] [8] . Adverse events may jeopardize the quality of life of patients, especially when the metastatic disease progresses after a first-line chemotherapy. It has been highlighted in a recent systematic literature analysis that there is a lack of predictive markers of response associated consistently with outcome in patients undergoing metronomic chemotherapy [25] . Therefore, identifying biomarkers that can predict adverse events of such chemotherapy would be important. In our study, grades 1-2 toxicity occurred in almost 35% of the patients, usually including hematologic and gastrointestinal adverse events. Here, we investigated the interaction of MTHFR C677T, MTHFR A1298C, and TSER 28 bp VNTR gene polymorphisms with the side effects and activity of mCAP chemotherapy. It is deemed Patients who developed at least one adverse event irrespective of type. that MTHFR 1298C and 677T variants can cause 5-FU toxicity by increasing the intracellular levels of 5,10-MTHF and consequently enhancing the formation and stability of the ternary inhibitory complex of 5-FU metabolites and TS.
The two MTHFR SNPs investigated in our study have been defined functionally by different studies with conflicting results [10, [26] [27] [28] [29] . However, in agreement with the results of previous studies [26] [27] [28] [29] , our data did not show any association between toxicity of fluoropyrimidine-based regimens and MTHFR polymorphisms.
Elevated intratumor TS levels have been observed frequently in gastric cancer patients with poor outcomes after 5-FU therapy [30] . Moreover, the presence of triple repeats (3R/3R) has been related to higher TYMS expression with consequent lower 5-FU efficacy [17, 31] . It is notable that a significant, inverse association of number of 28-bp tandem repeats in the promoter region and the severity of 5-FU toxicity has been reported [16 -19] . In particular, patients with the 2R/2R genotype were 20 times more likely to develop severe toxicity compared with 3R/3R carriers [18] .
In this study, we detected a relationship between the TSER 28 bp VNTR 2R/2R genotype and the development of hematologic and gastrointestinal toxicity in patients treated with mCAP. Notably, our results were consistent with other reports showing a higher risk of developing adverse events related to either 5-FU [16] [17] [18] [19] [20] or capecitabine [15, 21] in patients harboring such a gene variant. These observations would suggest that the presence of the 2R/2R genotype predicts toxicity not only following standard fluoropyrimidines chemotherapy but also when low doses of capecitabine are administered continuously.
Our results firstly indicated a relationship between toxicity of fluoropyrimidines delivered as a metronomic schedule and genetic variants of enzymes involved in 5-FU metabolism. Moreover, in contrast to other previous findings [20] , which referred both to different patients' settings (adjuvant and advanced) and chemotherapy regimens (monotherapy and fluoropyrimidine-based polychemotherapy), our study focused on patients with advanced gastrointestinal tumors treated homogeneously with a unique fluoropyrimidine protocol.
The degradation rate of 5-FU is a phenotypic marker of the 5-FU metabolism. We have recently observed a correlation between the DPYD polymorphism and the 5-FU degradation rate [22] . Moreover, patients with altered 5-FU degradation rate showed a high prevalence of severe (grades 3-4) toxicities after a fluoropyrimidinebased chemotherapy [23] . Thus, 5-FU degradation rate has been suggested as a putative biomarker of 5-FU toxicity. However, on account of the lack of severe toxicity in the present study, a relationship between the 5-FU degradation rate and the occurrence of adverse events could not be observed.
Conclusion
Our study has unveiled a relationship between the TSER polymorphism and toxicity related to metronomic oral fluoropyrimidines that could be considered to minimize the impact of therapy on patients' quality of life. However, further prospective studies are needed to confirm our results. 
